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Abstract 
Background: Multiple Sclerosis is chronic autoimmune inflammatory demylinative disease of the 
central nervous system that affects usually young ages. Cytomegalovirus still controversy and have 
either protective role in induction of multiple sclerosis disease via molecular mimicry. The current 
study was designed to assess the sero-prevalence of anti-Cytomegalovirus IgG in multiple sclerosis 
patients; its impacts if any association of Cytomegalovirus with either disease initiation and or disease 
activity. 
Materials and methods: The study was conducted in Rizgary teaching hospital Erbil /Iraq. Patients 
group enrolled comprised of 50 multiple sclerosis patients. The controls group comprised of 30 healthy 
persons with age and gender match. Anti-Cytomegalovirus IgG titer using enzyme- linked 
immunosorbent assay test was assessed in Multiple Sclerosis patients. 
Results: A total of 50 multiple sclerosis patients is enrolled in this study, 17 Patients (34 %) had 
Relapsing Remitting multiple sclerosis and 33 patients (66%) had secondary progressive pattern 
course. Common presenting symptoms were limb weakness, diplopia, visual obscuration, sensory 
impairment and ataxia. Results revealed a highly significant increase of anti-CMV IgG titer in MS 
patients compared with controls group; with higher titer in patients with more than 4-relapses that 
reflects disease activity.  
Conclusions: Seropositivity of Cytomegalovirus was higher in Multiple Sclerosis patients than 
controls; therefore, it may have a possible role in Multiple Sclerosis pathogenesis but further studies 
are needed to prove this result. 
 
Key words: Cytomegalovirus (CMV), Multiple Sclerosis (MS),   Enzyme linked immunosorbent assay 
(ELIZA), Extended disability status scale(EDSS)and Central nervous system (CNS). 
 
 
 
 
 
 
 
 
 
ARTICLE INFO 
Submission date: 26/8/ 2019 
Acceptance date: 19 / 11/ 2019 
Publication date: 31/ 12 / 2019 
Journal of University of Babylon for Pure and Applied Sciences, Vol. (27), No. (6): 2019 
 
108 
 
Introduction 
Multiple Sclerosis (MS) is the most common autoimmune inflammatory 
disease of central nervous system that cause inflammatory demyelination a 
progression cell loss and axonal degeneration within the central nervous system [1]. 
Since long time role of an environmental factors discussed that has an 
important factor in Multiple Sclerosis pathogenes is among these environmental risk 
factors, numerous infectious agents both viral and bacterial agent is investigated some 
of them approved that have role in its pathogenesis [2]. 
Several viruses have already been implicated as triggers and there are several 
studies that implicate members of the Herpesviridae family in the pathogenesis of 
MS. The most important characteristic of these viruses is that they have periods of 
latency and exacerbations within their biological sanctuary the central nervous 
system. The Epstein-Barr, Cytomegalovirus, human herpesvirus6 and human 
herpesvirus7 viruses are the members that are most studied as being possible triggers 
of multiple sclerosis [3]. 
Cytomegalovirus (CMV) is a member of the Herpesviridae (beta herpes virus) 
with a double-stranded DNA (235kb) that infects more than 40- 60 % of the general 
population and up to 100% within some subpopulations and / or geographic areas [1]. 
Cytomegalovirus may have a detrimental or beneficial role in MS pathology; 
thus the role is dispute [4]. CMV has been implicated as a co-etiological agent in 
brain cancer and associated with a wide range of inflammatory diseases [5]. CMV 
uses a variety of strategies that target host defenses from the disruption of antigen-
processing pathways to the modulation of cytokines [6] all of which may contribute to 
the success of CMV in establishing coexistence. During active infection CMV can be 
found in most tissues and organs as well as in most body fluids especially urine and 
saliva [7]. 
Other studies are indicative for a protective effect of CMV on autoimmune 
diseases. CMV infection is associated with anti-inflammatory activities which could 
lead to a less severe course of the disease [8]. It will establish lifelong latent infection 
in ≥ 70% of human population [4]. 
It is  mainly target cells of the myeloid lineage; can cross the blood brain 
barrier and has been detected in demyelinating plaques and the cerebrospinal fluid of 
MS patients [9,10]and causes demyelination mainly in the CNS of immune 
compromised host[11,12]. Based on CMV DNA and CMV- specific IgG antibody 
titers epidemiologic studies that support the role of CMV in MS pathology [1]. 
Accumulating evidence indicates that CMV contributes to MS 
pathophysiology via interplay of different mechanisms like molecular mimicry, 
bystander activation and epitope spreading [13]. 
The present study attempted to determine the sero-prevalnce of CMV in different 
specimens of Multiple Sclerosis patients to impact if any association of CMV with the 
disease. 
 
Materials and Methods 
The study is a case-control study, conducted in Rizgary teaching hospital Erbil 
/Iraq. The enrolled patient group comprised of 50 MS patients. The control group 
comprised of 30 healthy persons with a matched age and gender. The patients were 
treated with Beta- interferon. Verbal consent obtained from all patients and controls. 
According to criteria via clinical presentation and MRI the all patients was diagnosed 
and finding was supported by MS professional clinic team based on Revised 
McDonald criteria for diagnose of Multiple sclerosis [14].This study was approved by 
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the Ethic Committee at Erbil Medical Technical Institute/ Erbil Polytechnic 
University. The data was statistically analyzed by using the Graph pad prism software 
version 6 the applied tests are: ANOVA for single factor using Tukey ̕ s multiple 
comparison test and grouped t-test was used if the comparisons were between two 
variables. P value of ≤ 0.05 was considered statistically significant.  
All patients had at least one attack of CNS inflammation. Expanded Disability 
Status Scale (EDSS)score for all patients at time of interview were below scale 5.0 
except in cases with secondary progressive MS (SPMS).  
The sera subjected to ELISA test for detection of anti- CMV IgG antibody in 
both MS patients and control group. According to anti-CMV IgG kit (Vircell ) the 
sample with equivocal results must be retested and /or a new sample obtained for  
confirmation. Samples with indexes below 9 (U. /ml)were considered as not having 
IgG specific antibodies against cytomegalovirus. Samples with indexes above 11(U. 
/ml)were considered as having IgG specific antibodies against cytomegalovirus.   
 
Results and Discussion 
A total of 50 MS patients comprised of 38 females and 12 males with 30 
controls (19) females and (11) males were enrolled. Included, 17 Patients (34 %) had 
Relapsing Remitting multiple sclerosis (RRMS) and 33 patients (66%) had secondary 
progressive pattern Multiple sclerosis (SPMS) and common presenting symptoms 
were limbs weakness, double vision, visual impairment, sensory signs and loss of 
balance (ataxia). The mean titer of CMVIgG in MS group was 23.29 ± 0.6079 
vs16.27 ± 0.3804(U. /ml)in control group. 
Figure (1) shows the mean titer of CMV IgG in M.S. patients and control group. The 
result revealed highly significant differences P=0.0001. 
 
 
Figure (1): Mean titer of anti-CMVIgG in patients and control group 
 
Figure (2) show the differences between  CMV IgG titer among patients age 
groups. Statistically significan differences was recorded between different age groups 
P=0.0326.andhighest titer was recorded among ages ( 31-40). 
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Figure (2): Mean anti-CMVIgG titer according to age groups in MS patients. 
 
Figure (3) shows the titer was higher in female than male but with no significant 
value. P=0.0811 
 
 
Figure (3): Mean anti-CMVIgG titer according to gender 
 
Figure (4) delineate anti-CMV IgG titer in relation with symptomatic 
presentation. IgG titer has no significant differences between the different 
symptomatic presentation of MS.P=5.93. 
 
Figure (4): Mean anti-CMV IgG titer in relation to symptomatic presentation in 
MS patients 
Journal of University of Babylon for Pure and Applied Sciences, Vol. (27), No. (6): 2019 
 
111 
 
Figure (5) clarifies association between EDSS score and anti-CMV IgGtiter, this 
figure shows that despite the disease progression the titer is not significantly changed. 
P=0.2812. 
 
 
Figure (5): Relation between expanded disability status scale score and anti- 
CMVIgG titer in MS patients 
Figure(6) the relation between anti-CMVIgG titers and number of relapses, it 
reveals no statistically significant differences P= 0.7307; although the titers was 
higher in patients with more than 4- relapses of CNS inflammation. 
 
Figure (6): Relation between number of relapse and anti-CMVIgG titer in MS 
patients 
 
There is a different idea on the role of CMV in MS disease. Some supports a 
detrimental role of CMV, as whereas others believe that CMV is disease- limiting. 
Various studies have focused on CMV as a potential trigger of MS [15, 16]. 
In this study, the mean titer of anti-CMV in MS patients was significantly 
more than control with gradual increases of titer with progressing of the disease. 
Though the anti-CMV IgG titer were more than higher in patients with more than 4-
relapse. The results of the present study agree with Sanndgol et al.,2011 [1] who 
reported significant difference in anti-CMV IgG titer beside increased frequency of 
CMV-DNA in MS patients compared with control. Another study that produced by 
Horakovn et al., 2013 [17]found that the time to relapse decreased and the number of 
relapses increased with anti-CMV IgG positivity. Earlier study delineates a 
correlation between CMV Seropositivity titers and an increased MS disease risk [13] 
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in spite of Sundqvist et al., 2014 [18]that found CMV seropositivity was decreased 
risk of MS disease. 
In this study, symptomatic presentation in association with anti-CMV IgG titer 
revealed no significant difference although when MS present in sensory symptom the 
titer was higher than present in any other symptoms. The same finding hold true for 
relation between EDSS score and anti-CMV IgG titer in MS patients although titer 
was higher in patients with EDSS score above 5. Our results disagree with study of 
Zivadinov et al., 2006 [19]who refers that association exists between anti-CMV 
seropositivity, a higher titer and better clinical and MRI outcomes this is could be our 
study has small sample size. 
On the other hand, Wunsch et al., 2016 [14] show that the higher disease 
activity due to the elevating B-cell response to CM in MS patients experiencing an 
acute relapse according to the correlation between the frequencies of CMV and brain 
specific B-cells in MS patients[14]. 
Cytomegalovirus infection thus can lead to cell death and could therefore 
enhance autoimmunity as a result of the release of self-antigen from degenerating 
tissue [8]. 
Reactivation of CMV during ongoing MS could trigger the release of free 
virus in interstitial and cerebral fluids of the CNS [13]. 
 
Conclusions 
 Seropositivity of Cytomegalovirus in Erbil City/ Iraq MS patients is higher than 
controls so it may suggest a possible association between CMV and development of 
MS disease and further investigations with large number of patients are needed to 
confirm this finding. 
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 عددصبي المتمرض التصلب العاصابات الفيروس المضخم للخلايا ودراسة العلاقة بين 
 
 الخلاصة
العصبي المركزي حيث ان الجهاز  التي تصيبمرض التصلب العصبي المتعدد مرض مزمن من امراض الجهاز المناعي  ديع :الخلفية
يد في مرض التصلب قد يكون له دور ضار او مف الدراسات السابقة تشير الى ادلة على ان الفايروس المضخم للخلاياالبحوث  و 
مصل  وقد تم اجراء هذه الدراسة لتقييم مدى انتشار الفيروس المضخم للخلايا في الباثولوجية المناعية العصبي المتعدد من الناحية
 . مرضى متعددة التصلب ومدى تاثيره على المرضى التصلب العصبي المتعدد
 05ن التى تتألف مالمرضى و من  مجموعة تم اخذ حيث أربيل/ العراق. فيفي مستشفى رزكاري التعليمي الدراسة لقد تم اجراء :الاساليب
في الاعمار بين الفئتين و  بمع اخذ بالاعتبار التقار  عينة سيطرةشخصا صحيحا ك 03و تم اخذ  المتعدد. العصبي مرضى التصلب
 في كلا الفئتين.GgI-itnA surivolagemtyC و قد تم دراسة نسبة انتشار الفايروس  نوع  بين الجنسين
٪ ) مريضا  يعانون من الانتكاس التصلب  43( 71، كان المتعدد في هذه الدراسةالعصبي من مرضى التصلب  05من بين  النتائج:
هي  كانت العامة الظاهرة على المرضىو  ثانية . من الدرجة ٪) كان لها دورة نمط التقدم التدريجي 66مريضا ( 33المتعدد التصلب و 
لفايروس المضخم  GgIكشفت النتائج زيادة كبيرة جدا من عيار مضاد  لحسي والترنح.نقص ا ة،ضعف أطرافهم، شفع، التعمية البصري
في المرضى الذين يعانون من  الفايروس مع ارتفاع عيار .سيطرةالمتعدد مقارنة مع مجموعة الالعصبي لدى مرضى التصلب للخلايا 
 مدى النشاط المرضي لديهم. التي تعكسالاعراض المرضية في الجهاز العصبي  او الانتكاسات 4أكثر من 
 الذين يعانون من التصلب مرضىال يروس المضخم للخلايا أعلى فيانسبة انتشار الف كانتمن خلال هذا البحث لقد  :الاستنتاج
ي المرضى ف نسبة المرض ايجابي في ازدياد شخاص الصحيين وقد يكون لها دوراي الا سيطرةالمتعدد مقارنة بعينة ال العصبي
 المتعدد ولكن هناك حاجة لدراسات اخرى ابعد من ذلك لإثبات هذه النتيجة. العصبيالتصلب 
 
 
 
 
  
 
 
 
 
 
